Alvotech, AbbVie Deal Allows For Humira Biosimilar In 2023

By Tiffany Hu · March 9, 2022, 5:16 PM EST

Icelandic biopharmaceutical firm Alvotech has settled an intellectual property fight with AbbVie Inc. over Alvotech's proposed biosimilar version of AbbVie's blockbuster drug Humira, which is used to treat arthritis and other...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

Alvotech USA Inc. et al v. Abbvie Inc et al

Case Number

Court

Virginia Eastern

Nature of Suit

Patent

Date Filed

May 11, 2021

Case Title

Alvotech USA Inc. et al v. Abbvie Inc et al

Case Number

Court

Illinois Northern

Nature of Suit

830(Patent)

Date Filed

October 22, 2021

Recent Articles By Tiffany

June 13, 2023
Spinal Device Co. Gets $6M Bond Cut In Trade Secrets Suit
March 27, 2023
Wholesaler To Pay $33.4M In Abbott Labs Test Strips TM Row
February 16, 2023
TTAB Won't Let Diagnostic Co. Register 'NF-Light' TM
February 07, 2023
Instacart Co-Founder Hit With TRO In Trade Secrets Fight
January 20, 2023
Brand Battles: Uber Tries To Drive Out 'Uberhorny' Dating TM
January 04, 2023
TTAB Rejects Health Care Co.'s TM As Descriptive
March 21, 2022
Justices Skip $420M Secrets Suit, 'Candy Colors' Fight & More
February 25, 2022
Brand Battles: BetterUp Takes Aim At 'BetterHelp' Trademark
February 08, 2022
Sun Pharma, Lupin Agree To Drop Eye Pain Patent Dispute
February 07, 2022
Generics Co. Accuses Ex-Exec Of Swiping Trade Secrets